JOHN P. COOKE, MD, PHD
Osteopathic Medicine at Pasteur Dr, Palo Alto, CA
License number
California G70377
Category
Osteopathic Medicine
Type
Cardiovascular Disease
Address
Address
300 Pasteur Dr, Palo Alto, CA 94305
Phone
(650) 497-8000
Organization information
See more information about JOHN P. COOKE at bizstanding.comStanford University - John P Cooke MD
300 Pasteur Dr #A260, Palo Alto, CA 94304
Categories:
Cardiology Physicians & Surgeons
Phone:
(650) 723-6459 (Phone)
Professional information
Proteins And Methods Useful For Assessing Risk Of Cardiovascular Disease
US Patent:
2006003, Feb 16, 2006
Filed:
Oct 7, 2005
Appl. No.:
11/245171
Inventors:
Robert Balint - Palo Alto CA, US
John Cooke - Palo Alto CA, US
John Cooke - Palo Alto CA, US
International Classification:
A61K 38/46, C12N 9/64
US Classification:
424094600, 435226000
Abstract:
The invention relates to a mutant protein comprising at least a fragment of a mutant dimethylarginine dimethylaminohydrolase (DDAH) enzyme, wherein the fragment possesses an affinity for asymmetric N,N-dimethyl arginine (ADMA) and/or L,N-monomethylarginine (LNMMA), which exists at lower plasma levels than ADMA, and is deficient in hydrolyzing ADMA or LNMMA to citrulline, releasing citrulline, or both.
John Patrick Cooke, Palo Alto CA
Specialties:
Internal Medicine, Cardiovascular Disease, Cardiology
Work:
Stanford University
300 Pasteur Dr, Palo Alto, CA 94304 Stanford University
300 Pasteur Dr, Stanford, CA 94305
300 Pasteur Dr, Palo Alto, CA 94304 Stanford University
300 Pasteur Dr, Stanford, CA 94305
Education:
Wayne State University (1980)
Enhancement Of Vascular Function By Modulation Of Endogenous Nitric Oxide Production Or Activity
US Patent:
6642208, Nov 4, 2003
Filed:
Aug 15, 2001
Appl. No.:
09/930833
Inventors:
John P. Cooke - Palo Alto CA
Victor J. Dzau - Newton MA
Gary H. Gibbons - Atlanta GA
Victor J. Dzau - Newton MA
Gary H. Gibbons - Atlanta GA
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
A61K 4800
US Classification:
514 44, 4353201, 435325
Abstract:
Vascular function and structure is maintained or improved by long term administration of physiologically acceptable compounds which enhance the level of endogenous nitric oxide or other intermediates in the NO induced relaxation pathway in the host. Alternatively, or in combination, other compounds may be administered which provide for short term enhancement of nitric oxide, either directly or by physiological processes.
Enhancement Of Vascular Function By Modulation Of Endogenous Nitric Oxide Production Or Activity
US Patent:
6646006, Nov 11, 2003
Filed:
Feb 1, 2002
Appl. No.:
10/060252
Inventors:
John P. Cooke - Palo Alto CA
Victor J. Dzau - Newton MA
Gary H. Gibbons - Atlanta GA
Victor J. Dzau - Newton MA
Gary H. Gibbons - Atlanta GA
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Stanford CA
International Classification:
A23L 1305
US Classification:
514565, 424439, 424441, 426648, 426656
Abstract:
Vascular function and structure is maintained or improved by long term administration of physiologically acceptable compounds which enhance the level of endogenous nitric oxide or other intermediates in the NO induced relaxation pathway in the host. Alternatively, or in combination, other compounds may be administered which provide for short term enhancement of nitric oxide, either directly or by physiological processes.
Conductive Biopolymer Implant For Enhancing Tissue Repair And Regeneration Using Electromagnetic Fields
US Patent:
2012006, Mar 15, 2012
Filed:
Jul 15, 2011
Appl. No.:
13/184313
Inventors:
Michael Paukshto - Foster City CA, US
George Martin - Rockville MD, US
John Cooke - Palo Alto CA, US
George Martin - Rockville MD, US
John Cooke - Palo Alto CA, US
Assignee:
Fibralign Corporation - Sunnyvale CA
International Classification:
A61N 1/00
US Classification:
607 50
Abstract:
Embodiments of the present invention relate generally to the field of tissue repair and regeneration. More specifically, embodiments of the present invention relate to medical devices, materials or constructs, such as conductive biocompatible polymers having one or more networks of metal nanowires that enhance tissue repair and regeneration using electromagnetic fields.
Intramural Delivery Of Nitric Oxide Enhancer For Inhibiting Lesion Formation After Vascular Injury
US Patent:
5852058, Dec 22, 1998
Filed:
Aug 12, 1996
Appl. No.:
8/695792
Inventors:
John P. Cooke - Palo Alto CA
Tai T. Lim - Gillman Heights, SG
Alan C. Yeung - Hillsborough CA
Tai T. Lim - Gillman Heights, SG
Alan C. Yeung - Hillsborough CA
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
A61K 31195, A61K 3802, A61M 2510, A61N 130
US Classification:
514564
Abstract:
Vessels suffering vascular injury from angioplasty are treated with L-arginine intramurally. The incidents associated with restenosis are substantially reduced providing for a reduced incidence of restenosis as a result of the injury.
Methods Of Reducing Angiogenesis
US Patent:
7652038, Jan 26, 2010
Filed:
May 9, 2008
Appl. No.:
12/118373
Inventors:
John Cooke - Palo Alto CA, US
Christopher Heeschen - Frankfurt, DE
Michael Weis - Munich, DE
Christopher Heeschen - Frankfurt, DE
Michael Weis - Munich, DE
Assignee:
The Board of Trustees of the Leland Stanford Jr. University - Palo Alto CA
International Classification:
A61K 31/445, A61K 31/415, A61K 31/40, A61K 31/235, A61K 31/14
US Classification:
514315, 514386, 514408, 514410, 514533, 514642, 514659
Abstract:
The present invention provides methods of reducing angiogenesis in an individual. The methods generally involve administering to the individual an effective amount of a nicotinic acetyl choline receptor antagonist. The methods are useful to treat conditions associated with or resulting from angiogenesis, particularly pathological angiogenesis. The invention further provides methods of treating a condition associated with or resulting from angiogenesis.
Beta2-Microglobulin And C Reactive Protein (Crp) As Biomarkers For Peripheral Artery Disease
US Patent:
8227201, Jul 24, 2012
Filed:
Jun 26, 2008
Appl. No.:
12/147385
Inventors:
John P. Cooke - Palo Alto CA, US
Andrew Wilson - Palo Alto CA, US
Andrew Wilson - Palo Alto CA, US
Assignee:
Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
G01N 33/53, G01N 31/00
US Classification:
435 721, 435 2, 435 71, 436501, 436518, 436522, 422 50, 530300, 530350
Abstract:
The present invention relates to use of β-2-microglobulin (B2M or β2M) and C-reactive protein (CRP) levels as biomarkers of peripheral artery disease and/or atherosclerosis.
Cell-Free Synthesis Of Active Reprogramming Transcription Factors
US Patent:
2012020, Aug 16, 2012
Filed:
Jul 14, 2010
Appl. No.:
13/384209
Inventors:
William Yang - Stanford CA, US
Kedar Patel - Fremont CA, US
Yohannes T. Ghebremariam - Stanta Clara CA, US
Ji Eun Lee - Menlo Park CA, US
John P. Cooke - Palo Alto CA, US
James Robert Swartz - Menlo Park CA, US
Kedar Patel - Fremont CA, US
Yohannes T. Ghebremariam - Stanta Clara CA, US
Ji Eun Lee - Menlo Park CA, US
John P. Cooke - Palo Alto CA, US
James Robert Swartz - Menlo Park CA, US
International Classification:
C12P 21/00
US Classification:
435 681
Abstract:
Compositions and methods are provided for the cell-free synthesis of active reprogramming factor polypeptides. The reprogramming factors may be synthesized as fusion proteins comprising a permeant domain, such as polyarginme. The cell free-synthesis may be conducted at about 25 C in a bacterial cell extract from genetically alterd cells having decreased endogenous protease activity Further, the proteins may comprise a fusion partner which enhances solubility and may be refolded on a column.
Method And Composition For Inhibiting Cardiovascular Cell Proliferation
US Patent:
2006015, Jul 20, 2006
Filed:
Dec 20, 2005
Appl. No.:
11/316304
Inventors:
John Cooke - Palo Alto CA, US
Garrison Fathman - Portola Valley CA, US
Jonathan Rothbard - Woodside CA, US
Shiro Uemura - Palo Alto CA, US
Robert Robbins - Stanford CA, US
Murray Kown - Menlo Park CA, US
Garrison Fathman - Portola Valley CA, US
Jonathan Rothbard - Woodside CA, US
Shiro Uemura - Palo Alto CA, US
Robert Robbins - Stanford CA, US
Murray Kown - Menlo Park CA, US
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
A61F 2/02
US Classification:
424423000, 514002000
Abstract:
Cardiovascular cell proliferation in a blood vessel subjected to trauma, such as angioplasty, vascular graft, anastomosis, or organ transplant, can be inhibited by contacting the vessel with a polymer consisting of from 6 to about 30 amino acid subunits, where at least 50% of the subunits are arginine, and the polymer contains at least six contiguous arginine subunits. Exemplary polymers for this purpose include arginine homopolymers 7 to 15 subunits in length.